Search Medical Condition
Please enter condition
Please choose location

Idiopathic Pulmonary Fibrosis Clinical Trials

A listing of Idiopathic Pulmonary Fibrosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (61) clinical trials

Winthrop University Hospital Clinical Trials Center is seeking volunteers who have been diagnosed with Idiopathic Pulmonary Fibrosis, a condition which decreases lung function. This study is testing an investigational medication to see if it is safe and effective. Eligible participants will receive study related medical care and study medication at ...

Phase

This research study is evaluating patients newly diagnosed with idiopathic pulmonary fibrosis (IPF) to assist in the development of future treatment options. This research study may be an option if you: Have been diagnosed with IPF within the last 6 months Are at least 40 years of age or older ...

Phase N/A

Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry

Phase N/A

We anticipate a number of observational studies will be developed from the data collected in the IPF-PRO registry. All planned analyses will be performed by the DCRI statistical team. Planning of the analyses will be done as a coordinated effort between the teams at the DCRI and Boehringer Ingelheim (refer ...

Phase N/A

The objective of the trial is to investigate the efficacy and safety of 150 mg bid nintedanib in patients with PF-ILD compared to placebo over 52 weeks (Part A). The primary objective is to demonstrate a reduction in lung function decline, as measured by the annual rate of decline in ...

Phase

Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment

The Chronic Hypersensitivity Pneumonitis (HP), is a complex syndrome due to a exaggerated immune response caused by inhalation of foreign substances, such as molds, dusts, and organic particles, causing alveoli inflammation and in the chronic forms the disease has high rate of mortality, due to the big number of patients ...

Phase

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

This is an open-label, staggered dose-escalation, cohort expansion study that will enroll subjects at multiple study sites in the United States of America (USA) and Australia. The study will consist of two treatment arms: - Low dose (100 mg) CC-90001 administered orally once daily (QD) for 12 continuous weeks. - ...

Phase